Keywords: map, drops, pediatric, asthma, drug, misses, ph

MAP drops 77% as pediatric asthma drug misses Ph III endpoints

Article | 02 March 2009

Print This

Shares in the USA's MAP Pharmaceuticals plummeted 77% on February 24, after the firm's experimental pediatric drug for asthma failed to meet ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in